Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 0,43€(−40,28%). Der Median liegt bei 0,43€(−40,28%).
| Kaufen | 3 |
| Halten | 1 |
| Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit
In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / June 5, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that Sandra Silberman, M.D., Ph.D., Chief Medical Officer of CNS Pharmaceuticals, will present at the Lenox Hill Hospital, Department of Neurosurgery's Brain Tumor Biotech Summit being held on June 5, 2025 in New York, NY.» Mehr auf accessnewswire.com
CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update
Cash expected to fund operations into the second half of 2026 Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / May 16, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the first quarter ended March 31, 2025 and provided a corporate update. "Our company remains focused as tightly as ever on neuro-oncology drug development.» Mehr auf accessnewswire.com
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the pricing of its "reasonable best efforts" public offering with a single healthcare focused institutional investor for the purchase and sale of 3,952,570 shares of common stock of the Company (the "Common Stock) (or common stock equivalents in lieu thereof), at a purchase price of $1.265 per share of Common Stock. The Company further agreed to issue to the investors Series F Common Stock purchase warrants to purchase up to 3,952,570 shares of Common Stock (the "Series F Warrants").» Mehr auf accessnewswire.com
Unternehmenszahlen
| (EUR) | März 2025 | |
|---|---|---|
| Umsatz | 0,00 | - |
| Bruttoeinkommen | 0,00 | 100,00% |
| Nettoeinkommen | −3,98 Mio | 21,05% |
| EBITDA | −4,01 Mio | 22,33% |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 3,54 Mio€ |
Anzahl Aktien | 5,46 Mio |
52 Wochen-Hoch/Tief | 170,99€ - 0,62€ |
| Dividenden | Nein |
Beta | 0,78 |
KGV (PE Ratio) | −0,13 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | 0,19 |
KUV (PS Ratio) | 1.320,26 |
Unternehmensprofil
| Name | CNS PHARMAC. INC. DL-,001 Aktie |
| CEO | John Michael Climaco Esq., J.D. |
| Mitarbeiter | 4 |
Assets entdecken
Shareholder von CNS PHARMAC. INC. DL-,001 Aktie investieren auch in folgende Assets
